Abstract
111In-DOTA-exendin-4 SPECT/CT has been shown to be highly efficient in the detection of insulinomas. We aimed at determining whether novel PET/CT imaging with [Nle14, Lys40(Ahx-DOTA-68Ga)NH2]exendin-4 (68Ga-DOTA-exendin-4) is feasible and sensitive in detecting benign insulinomas. Methods: 68Ga-DOTA-exendin-4 PET/CT and 111In-DOTA-exendin-4 SPECT/CT were performed in a randomized cross-over order in 5 patients with endogenous hyperinsulinemic hypoglycemia. Gold standard for comparison was the histological diagnosis after surgery. Results: In 4 patients histological diagnosis confirmed a benign insuIinoma, whereas one patient refused surgery despite a positive 68Ga-DOTA-exendin-4 PET/CT scan. In 4 out of 5 patients previously performed conventional imaging (CT/MRI) was not able to localize the insulinoma. 68Ga-DOTA-exendin-4 PET/CT correctly identified the insulinoma in 4/4 patients whereas 111In-DOTA-exendin-4 SPECT/CT correctly identified the insulinoma in 2/4 patients. Conclusion: These preliminary data suggest that 68Ga-DOTA-exendin-4 PET/CT is feasible in detecting hidden insulinomas.
- Neuroendocrine
- Oncology: Endocrine
- PET/CT
- exendin-4
- gallium-68
- glucagon-like peptide-1 receptor targeting
- insulinoma
- Copyright © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.